Assessing Whether Adobe (ADBE) Is Undervalued As AI Competition Pressures Its Growth Story

Adobe (ADBE) is back in focus after Inspired Thinking Group said it will plug Adobe Firefly’s generative AI into its Storyteq content marketing platform, pairing Firefly with ITG’s Halo Intelligence for AI driven content workflows.

See our latest analysis for Adobe.

Despite Adobe’s push to embed Firefly into real world workflows like ITG’s Storyteq platform, sentiment has stayed cautious, with a 30 day share price return of 18.4% and a 1 year total shareholder return decline of 33.5%, pointing to fading momentum and ongoing concerns about AI driven disruption.

If you are weighing how AI is reshaping software leaders like Adobe, this can be a good moment to broaden your search with high growth tech and AI stocks for other potential ideas.

With Adobe stock down sharply over 1 and 5 years and trading at what some see as an unusually wide gap to analyst targets, you have to ask: is this a mispriced AI heavyweight, or is the market correctly discounting future growth?

Advertisement

Most Popular Narrative: 24.2% Undervalued

According to Imperial, the narrative pegs Adobe’s fair value at US$383.06 per share, compared with the last close of US$290.37, suggesting a meaningful gap worth understanding.

The key catalyst is the enterprise adoption of Adobe's generative AI, Firefly. Its "commercial-safe" status, a direct result of being trained on licensed assets, gives it a powerful advantage over competitors in the corporate world where copyright infringement is a major legal concern. This allows Adobe to tap into the durable industry tailwind of digital transformation, leveraging its existing enterprise relationships to drive meaningful new revenue and defend its pricing power.

Read the complete narrative.

Want to see how this story arrives at that fair value? It leans on specific assumptions around revenue growth, margins, and the earnings multiple Adobe could sustain. Curious which numbers carry the most weight here?

Result: Fair Value of $383.06 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on Firefly gaining real traction and Adobe holding off rivals like Figma and Midjourney; setbacks here could quickly weaken the underpriced thesis.

Find out about the key risks to this Adobe narrative.

Build Your Own Adobe Narrative

If you do not fully agree with this view or prefer to rely on your own research, you can quickly build a version grounded in your assumptions with Do it your way.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Adobe.

Looking for more investment ideas?

If Adobe has you thinking harder about where AI and software fit in your portfolio, do not stop here. Widen your search before the next opportunity moves on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:ADBE

Adobe

Operates as a technology company worldwide.

Undervalued with adequate balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
48 users have followed this narrative
2 users have commented on this narrative
8 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7720.1% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
83 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
190 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0